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Abstract 
Background: Randomized controlled trials (RCTs) suggest that supplementation with omega-3 polyunsaturated 
fatty acids (n-3PUFAs) may favourably modify cardiometabolic biomarkers in type 2 diabetes (T2DM). Previous meta-
analyses are limited by insufficient sample sizes and omission of meta-regression techniques, and a large number of 
RCTs have subsequently been published since the last comprehensive meta-analysis. Updated information regarding 
the impact of dosage, duration or an interaction between these two factors is therefore warranted. The objective was 
to comprehensively assess the effect of n-3PUFAs supplementation on cardiometabolic biomarkers including lipid 
profiles, inflammatory parameters, blood pressure, and indices of glycaemic control, in people with T2DM, and identify 
whether treatment dosage, duration or an interaction thereof modify these effects.
Methods: Databases including PubMed and MEDLINE were searched until 13th July 2017 for RCTs investigating the 
effect of n-3PUFAs supplementation on lipid profiles, inflammatory parameters, blood pressure, and indices of glycae-
mic control. Data were pooled using random-effects meta-analysis and presented as standardised mean difference 
(Hedges g) with 95% confidence intervals (95% CI). Meta-regression analysis was performed to investigate the effects 
of duration of supplementation and total dosage of n-3PUFAs as moderator variables where appropriate.
Results: A total of 45 RCTs were identified, involving 2674 people with T2DM. n-3PUFAs supplementation was 
associated with significant reductions in LDL [ES: − 0.10, (95% CI − 0.17, − 0.03); p = 0.007], VLDL (ES: − 0.26 (− 0.51, 
− 0.01); p = 0.044], triglycerides (ES: − 0.39 (− 0.55, − 0.24; p ≤ 0.001] and HbA1c (ES: − 0.27 (− 0.48, − 0.06); p = 0.010]. 
Moreover, n-3PUFAs supplementation was associated with reduction in plasma levels of TNF-α [ES: − 0.59 (− 1.17, 
− 0.01); p = 0.045] and IL-6 (ES: − 1.67 (− 3.14, − 0.20); p = 0.026]. All other lipid markers, indices of glycaemic control, 
inflammatory parameters, and blood pressure remained unchanged (p > 0.05).
Conclusions: n-3PUFAs supplementation produces favourable hypolipidemic effects, a reduction in pro-inflamma-
tory cytokine levels and improvement in glycaemia. Neither duration nor dosage appear to explain the observed 
heterogeneity in response to n-3PUFAs.
Trial registration This trial was registered at http://www.crd.york.ac.uk as CRD42016050802
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to draw inferences regarding dosage, duration and the 
interaction of dosage and duration of n-3PUFA intake 
[17–20]. Furthermore, since publication of the most-
comprehensive meta-analysis almost a decade ago [20], a 
considerable number of well-controlled RCTs have been 
published.
A primary goal of diabetes management is to establish 
effective adjunct treatments which act to reduce CVD 
risk [23]. Information which helps to comprehensively 
characterise the impact of n-3PUFAs on cardiometa-
bolic biomarkers in people with T2DM is much needed, 
and could offer valuable insight into the therapeutic use 
of n-3PUFA supplementation. Therefore, the purpose of 
this review was to perform a meta-analysis and meta-
regression of RCTs to provide the most contemporary 
and comprehensive assessment to date concerning the 
effects of n-3PUFAs on cardiometabolic biomarkers 
including lipid profiles, inflammatory parameters, blood 
pressure, and indices of glycaemic control in T2DM. We 
aimed to model whether duration, dosage, or an inter-
action of duration and dosage, influences biomarkers of 
interest, to identify treatments patterns that may yield 
the greatest therapeutic benefit.
Methods
Data sources and searches
This meta-analysis was conducted in accordance with 
PRISMA (Preferred Reporting Items for Systematic 
Review and Meta-analyses) guidelines [24] and prospec-
tively registered. Databases were searched including Pub-
Med and The Cochrane Library as well as MEDLINE, 
SPORTDiscus, PsycINFO and CINAHL, via EBSCOhost, 
by LLO, JM and KD up to the 13th July 2017. For search 
terms see Additional file 1: Table S1. No language or date 
of publication restrictions were applied during the litera-
ture search. Reference lists of eligible RCTs and review 
articles were also searched to identify additional relevant 
trials. Corresponding authors were contacted by e-mail 
and asked to provide data on two occasions where; (i) 
only the abstract or partial data was available; (ii) com-
bined results had been reported for those with and with-
out diabetes or those with and without other significant 
medical conditions.
Eligibility criteria
Two reviewers (LLO and JM) independently reviewed all 
RCTs by title and abstract and subsequently by full text 
evaluation. Discrepancies which arose during this pro-
cess were resolved by a third reviewer (KD). RCTs (either 
Background
Cardiovascular disease (CVD) is the leading cause of 
morbidity and mortality in people with type 2 diabetes 
(T2DM) [1]. While treatment for T2DM predominantly 
focuses on improving glycaemic control, lowering glu-
cose only marginally reduces cardiovascular risk [2–6]. 
Conversely, targeted correction of clustered cardiometa-
bolic biomarkers (e.g. lipid parameters, inflammatory 
markers, and blood pressure) have been shown to mark-
edly reduce CVD risk and mortality in T2DM [7].
Such risk factors are highly amenable to dietary modi-
fication [8], and dietary habits account for a substantial 
proportion of CVD-related deaths [9]. Recent studies 
have identified suboptimal intake of omega-3 polyun-
saturated fatty acids (n-3PUFAs) to be a key individual 
dietary component associated with premature cardiomet-
abolic mortality [9]. Observational studies consistently 
report independent associations between high n-3PUFA 
intake and low cardiometabolic risk [10] and the pleio-
tropic effects of n-3PUFAs on cell functioning that affect 
blood lipids, inflammation, and endothelial function are 
well established [11, 12]. These epidemiologic studies, 
as well as in vitro and in vivo data, have prompted ran-
domised controlled trials (RCTs) to determine whether 
n-3PUFA supplementation can modify cardiometabolic 
biomarkers. For example, data suggest that n-3PUFA 
may improve postprandial hypertriglyceridemia, hyper-
glycaemia, insulin secretion ability and endothelial func-
tion in patients with impaired glucose metabolism and 
coronary heart disease [13]. In T2DM supplementation 
with n-PUFA has been shown to improve glucose, waist 
circumference, and insulin and homeostatic model of 
insulin resistance (HOMA-IR) [14]. However, it has also 
recently been reported that n-3PUFA fail to exert ben-
eficial effects on oxidative and inflammatory parameters 
[15], despite improvements in triglycerides [15]. Nor 
were improvements observed in coagulation, metabolic, 
and inflammatory status in well-controlled patients with 
atherosclerotic vascular disease and T2DM [16].
Whilst several meta-analyses have been performed in 
T2DM, variable degrees of benefit on these biomarkers 
have been reported [17–21]. Significant heterogeneity of 
effect between primary trials has been observed [19–21], 
which is likely to have arisen, at least in part, as a result 
of variable supplementation dosage and duration, either 
of which may modify the effects of n-3PUFAs on cardio-
metabolic biomarkers [22]. Moreover, previous meta-
analyses are limited by statistical power and omission 
of meta-regression techniques which limits the ability 
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parallel or crossover designs) comparing the effects of 
n-3PUFAs with placebo control on outcomes of inter-
est amongst adults with T2DM were included in the 
meta-analysis. All n-3PUFA interventions were in diet 
or capsule form and included if the dosage and duration 
could be determined. When RCTs assessed the effects 
of n-3PUFAs in conjunction with other nutrients or 
interventions, data were extracted from arms assessing 
n-3PUFA and placebo only. RCTs conducted in animal 
models, other forms of diabetes (e.g. type 1 diabetes, ges-
tational diabetes), or in people under 18 years of age were 
excluded (Fig. 1 shows trial selection).
Data extraction and quality assessment
Data extraction was conducted independently by two 
authors (LLO and MDC) with discrepancies adjudicated 
by a third author (KD). Data were extracted into a stand-
ardised spreadsheet, which included (i) trial information 
(first author, year of publication, corresponding author 
name and email); (ii) trial characteristics (design, num-
ber of trial arms, total duration, blinding); (iii) participant 
characteristics (gender, age, body mass, nationality, dura-
tion of diabetes and complications), and (iv) intervention 
specifics (type of n-3PUFA, placebo, duration, dosage, 
and number of participants per trial arm). Additionally, 
pre- and post-intervention mean and SD values were 
extracted, for: HbA1c (%, mmol/mol), fasting plasma 
glucose (FPG) (mmol  L−1), fasting insulin (pmol  L−1), 
HOMA-IR, C-peptide (nmol  L−1), triglycerides 
(mmol  L−1), total cholesterol (mmol  L−1), high density 
lipoprotein (HDL) (mmol L−1), LDL (mmol L−1), very low 
density lipoprotein cholesterol (VLDL-C) (mmol  L−1), 
very low density lipoprotein triglycerides (VLDL-TG) 
(mmol  L−1), apolipoprotein-A1 (g  L−1), apolipoprotein-
B (g L−1), non-esterified fatty acids (NEFA) (mmol L−1/
ng mL−1), C-reactive protein (CRP) (nmol L−1), tumour 
necrosis factor alpha (TNF-α) (pg  mL−1), interleukin 6 
(IL-6) (pg mL−1), systolic blood pressure (SBP) (mmHg), 
and diastolic blood pressure (DBP) (mmHg). When val-
ues were presented in figure form only, the figure was 
digitized using graph digitizer software (DigitizeIt, Ger-
many) and the means and SD/SEM were measured man-
ually at the pixel level to the scale provided.
Two independent reviewers (LLO and MDC) assessed 
the risk of bias in included trials using The Cochrane Col-
laboration’s tool for assessing risk of bias [25]. Each RCT 
was given one of three rankings, ‘high risk’, ‘low risk’, or 
‘unclear risk’, in each of the following domains: sequence 
generation, allocation concealment, blinding of par-
ticipants, personnel and outcome assessors, incomplete 
outcome data, selective outcome reporting and other 
sources of bias. Discrepancies which arose during this 
process were resolved firstly by discussion then by a third 
reviewer where necessary (KD). Risk of bias outcomes 
are presented within Additional file 1: Figures S1, S2.
Data synthesis and analysis
If not reported, standard deviations were calculated from 
standard errors, confidence intervals (CI), or interquar-
tile ranges [26]. Outcome measures were converted into 
the standardised mean difference (SMD) expressed as 
Hedges’ g with 95% CI. Correction using Hedges’ g is 
believed to yield an unbiased estimate of effect size [27]. 
A random-effects meta-analysis was performed [27] 
by LLO and KD using Comprehensive Meta-Analysis 
Software (Version 3, Biostat, Englewood, NJ, USA). The 
inputted data included sample sizes, outcome measures 
with their respective standard deviations, and a corre-
lation coefficient for within-subject measurements for 
crossover designs. These correlation coefficients were 
estimated from prior trials in our laboratory and other 
published trials, and were as follows: HbA1c r = 0.90, 
fasted plasma glucose r = 0.62, fasted insulin r = 0.41, 
HOMA-IR r = 0.72, C-peptide r = 0.90, triglycerides 
r = 0.79, total cholesterol r = 0.90, HDL r = 0.60, LDL 
r = 0.89, VLDL-C r = 0.72, VLDL-TG r = 0.72, apolipo-
protein-A1 r = 0.72, apolipoprotein-B r = 0.18, NEFA 
r = 0.30, CRP r = 0.81, TNF-α r = 0.94, IL-6 r = 0.90, SBP 
r = 0.80, DBP r = 0.80.
SMD values of < 0.20 were interpreted as trivial, 0.20–
0.39 as small, 0.40–0.80 as moderate and > 0.80 as large 
[28]. A negative effect size (ES) favours n-3PUFA sup-
plementation in the respective outcome variable while a 
positive ES favours the control. Heterogeneity between 
RCTs was assessed using the  I2 statistic, where 0–20% 
suggests heterogeneity may be trivial, 20–50% represents 
low heterogeneity, 50–75% represent moderate heteroge-
neity, and 75% and above represents high heterogeneity 
[29]. This measure of heterogeneity was complimented 
by also reporting the Tau-squared statistic and the Chi 
squared statistic. To examine whether the results were 
affected markedly by a single trial, sensitivity analyses 
were performed on all outcome variables by iteratively 
omitting one trial at a time. Where significant effects of 
n-3PUFA on outcome measures were observed, post hoc 
meta-regression analysis (method-of-moments model) 
was performed where 10 or more trials were available to 
model the effect [27]. This analysis was used to determine 
whether duration, dosage, or both continuous modera-
tor variables combined could explain the variation in ES 
between trials.
Results
In total 5662 titles were found through database searches, 
of these 45 RCTs were eligible and included in the quan-
titative synthesis and meta-analysis (Fig.  1). A total of 
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Fig. 1 Flowchart of trial selection
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2674 adults aged between 33 and 70 years with a T2DM 
diagnosis of between 1 and 19 years were included. The 
dose of total n-3PUFAs ranged from 0.40 to 18.00  g, 
with duration of supplementation lasting 2–104  weeks. 
n-3PUFAs were typically administered in capsule form, 
except on two occasions where a sardine-enriched diet 
or liquid form of n-3PUFA was administered. Of the 45 
RCTs 69% (n = 31) investigated lipid and lipoprotein pro-
files, 42% (n = 19) inflammatory parameters and blood 
pressure, and 80% (n = 36) indices of glycaemic con-
trol. Primary outcomes of each study are provided (see 
Additional file 1: Table S7). Descriptive and raw data of 
included RCTs are provided: See Additional file 1: Tables 
S2–S5.
Lipid and lipoprotein profiles
Supplementation with n-3PUFAs resulted in a trivial 
decrease in LDL (ES: − 0.10, 95% CI − 0.17 to − 0.03; 
p = 0.007; Fig.  2), the degree of heterogeneity between 
these RCTs was also trivial (I2 = 0.00%; Q = 21.60, 
τ2 = 0.00, df = 27). There was a small significant decrease 
in triglycerides following n-3PUFA supplementation 
(ES: − 0.39, 95% CI − 0.55 to − 0.24; p ≤ 0.001; Fig.  3), 
with moderate heterogeneity observed between RCTs 
(I2 = 69.40%, Q = 101.20, τ2 = 0.13, df = 31). n-3PUFAs 
were associated with a small significant decrease in 
VLDL-C (ES: − 0.26, 95% CI − 0.51 to − 0.01; p = 0.044; 
Fig. 4a), the degree of heterogeneity between these RCTs 
was low (I2 = 49.70%; Q = 9.90, τ2 = 0.04 and df = 5). Sen-
sitivity analysis, performed to determine the independent 
effect of each trial on the overall effect size, revealed the 
independent removal of four single comparisons moder-
ated the statistical interpretation of VLDL-C from signifi-
cant to non-significant. There was a significant moderate 
reduction in VLDL-TG following n-3PUFA supplemen-
tation (ES: − 0.40, 95% CI − 0.74 to − 0.06; p = 0.021; 
Fig.  4b) the degree of heterogeneity between RCTs was 
low (I2 = 48.00%; Q = 5.80, τ2 = 0.06 and df = 3). The sta-
tistical interpretation of VLDL was changed from sig-
nificant to non-significant by the independent removal 
of two RCTs. HDL (ES: − 0.09, 95% CI − 0.18 to 0.01; 
p = 0.067), total cholesterol (ES: − 0.03, 95% CI − 0.16 to 
0.22; p = 0.733), NEFA (ES: − 0.96, 95% CI − 2.20 to 0.28; 
p = 0.128), apolipoprotein-A1 (ES: 0.03, 95% CI − 0.12 to 
0.19; p = 0.656), and apolipoprotein-B (ES: 0.03, 95% CI 
− 0.25 to 0.30; p = 0.859) did not change significantly fol-
lowing n-3PUFA supplementation. Sensitivity analysis 
revealed that for HDL, the exclusion of three single com-
parisons in turn moderated the statistical interpretation 
of the results from non-significant to significant, result-
ing in a favourable increase in HDL following n-3PUFA 
supplementation compared to placebo.
Inflammatory parameters and blood pressure
There was a significant moderate reduction in TNF-α fol-
lowing n-3PUFA supplementation (ES: − 0.68, 95% CI 
− 1.32 to − 0.03; p = 0.039; Fig. 5a); the degree of hetero-
geneity was high between RCTs  (I2 = 82.10%, Q = 27.90, 
τ2 = 0.52, df = 5). Sensitivity analysis for TNF-α revealed 
the removal of three single comparisons in turn mod-
erated the statistical interpretation of the results from 
significant to non-significant. IL-6 was seen to decrease 
with a large ES (ES: − 1.67, 95% CI − 3.14 to − 0.20; 
p = 0.026; Fig. 5b); the degree of heterogeneity was high 
between RCTs (IL-6:  I2 = 93.50%, Q = 61.60, τ2 = 2.35, 
df = 4). Sensitivity analysis for IL-6 revealed that the 
independent removal of one RCT moderated the sta-
tistical interpretation of the results from significant to 
non-significant. CRP did not change significantly with 
n-3PUFAs (ES: − 0.53, 95% CI − 1.28 to 0.21; p = 0.159), 
sensitivity analysis revealed that the removal of one com-
parison changed the results from non-significant to sig-
nificant. n-3PUFAs had no significant effect on SBP (ES: 
0.00, 95% CI − 0.15 to 0.14; p = 0.957) or DBP (ES: 0.04, 
95% CI − 0.08 to 0.17; p = 0.508).
Indices of glycaemic control
There was a small yet significant reduction in HbA1c 
following n-3PUFA supplementation (ES: − 0.27, 95% 
CI − 0.48 to − 0.06; p = 0.010), the degree of hetero-
geneity was high between included RCTs (I2 = 88.60%, 
Q = 281.10, τ2 = 0.28,  df = 32; Fig.  6). Sensitivity analy-
sis for HbA1c revealed that the independent removal of 
two RCTs moderated the statistical interpretation of the 
results from significant to non-significant. All other indi-
ces of glycaemic control were not significantly different 
following n-3PUFA supplementation; FPG (ES: 0.07, 95% 
CI − 0.03 to 0.17; p = 0.177), fasting insulin (ES: − 0.12, 
95% CI − 0.27 to 0.03; p = 0.105), HOMA-IR (ES: − 0.16, 
95% CI − 0.37 to 0.05; p = 0.145), C-peptide (ES: 0.13, 
95% CI − 0.14 to 0.41; p = 0.345).
Meta regression
Meta-regressions were performed for significant out-
comes with more than 10 RCTs; neither duration of 
supplementation nor dosage of n-3PUFAs statistically 
explained heterogeneity (i.e. variation in effect sizes) 
observed in these analyses (Table 1).
Small study effects
Inspection of the funnel plots (Additional file  1: Figure 
S3) and Egger’s regression intercept revealed that there 
was little evidence of small study effects for triglycer-
ides (intercept: − 0.78, 95% CI − 2.35 to 0.80; p = 0.32), 
LDL (intercept: − 0.49, 95% CI − 0.22 to 1.19; p = 0.17), 
TNF-α (intercept: − 3.50, 95% CI − 14.58 to 7.58; 
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p = 0.43), and HbA1c (intercept: − 1.52, 95% CI − 3.40 to 
0.36; p = 0.11). There was evidence of small study effects 
for VLDL-C (intercept: − 2.38, 95% CI − 4.39 to − 0.36; 
p = 0.03), VLDL-TG (intercept: − 2.89, 95% CI − 5.49 
to − 0.30; p = 0.04), and IL-6 (intercept: − 9.63, 95% CI 
− 10.75 to − 8.50; p = <0.001).
Discussion
Our meta-analysis and meta-regression provides the 
largest, most comprehensive, and contemporary review 
to date assessing the impact of n-3PUFAs on cardiometa-
bolic biomarkers in T2DM. Considering the cumulative 
trial data from 45 pooled RCTs with a total of 2674 adults 
Fig. 2 Forest plot of effect sizes (means ± 95% confidence intervals) for trials evaluating the effect of n-3PUFAs on low density lipoprotein 
cholesterol amongst adults with type 2 diabetes
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Fig. 3 Forest plot of effect sizes (means ± 95% confidence intervals) for trials evaluating the effect of n-3PUFAs on triglycerides amongst adults with 
type 2 diabetes
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with T2DM, compared with placebo, n-3PUFA treatment 
was associated with significant hypolipidemic and anti-
inflammatory effects, as well as a small but significant 
reduction in HbA1c. These improvements were not mod-
erated by treatment duration, dosage, or an interaction 
between these two factors.
It is well established that T2DM is associated with dys-
lipidaemia (4). n-3PUFA intake has long been indicated 
in the treatment of hypertriglyceridemia [30, 31], pro-
moting reductions in hepatic TG synthesis and accel-
erating triglyceride clearance [32–34]. We observed a 
small reduction in triglycerides in response to n-3PUFA 
intake accompanied by reductions in both VLDL-TG and 
VLDL-C which is largely consistent with previous find-
ings [17–21]. However, contrary to previous meta-anal-
yses [17–20], our analysis shows that n-3PUFA intake 
does not result in an unfavourable increase in LDL. This 
is an important observation, as LDL is an independent 
predictor of CVD risk, and treatment aimed at lowering 
LDL levels have shown CVD benefits and reduction in 
mortality [35, 36]; thus, LDL reduction is a principle tar-
get of primary prevention of CVD for the American Col-
lege of Cardiology and the American Heart Association 
[37].
Previous research has highlighted, the magnitude of 
change in LDL is potentially dependent upon baseline 
triglyceride levels and may also differ between puri-
fied eicosapentaenoic acid (EPA)/docosahexaenoic acid 
(DHA) treatments and combined preparations [38]. We 
did not find improvements in total cholesterol, HDL, or 
apolipoproteins, which is consistent with previously pub-
lished studies [18–20].
This is the first meta-analysis to show significant 
improvements in the inflammatory cytokines TNF-α 
and IL-6 in people with T2DM in response to n-3PUFA 
intake. Low grade inflammation is a pathologic mediator 
of vascular complications in T2DM [39], and the mag-
nitude of cardiometabolic risk associated with plasma 
Fig. 4 Forest plot of effect sizes (means ± 95% confidence 
intervals) for trials evaluating the effect of n-3PUFAs on very low 
density lipoprotein cholesterol (a) and very low density lipoprotein 
triglycerides (b) amongst adults with type 2 diabetes
Fig. 5 Forest plot of effect sizes (means ± 95% confidence intervals) 
for trials evaluating the effect of n-3PUFAs on TNF-α (a) and IL-6 (b) 
amongst adults with type 2 diabetes
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Fig. 6 Forest plot of effect sizes (means ± 95% confidence intervals) for trials evaluating the effect of n-3PUFAs on HbA1c amongst adults with type 
2 diabetes
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levels of acute-phase reactants [40, 41] is similar to that 
in isolated dyslipidaemia and hypertension [39, 42]. Epi-
demiological, cellular, and molecular data support T2DM 
as a state of amplified inflammation [43, 44]; which is 
associated with a heightened atherosclerotic and pro-
thrombotic milieu [44], pathophysiologic insulin resist-
ance [45, 46], and pancreatic cell apoptosis [47]. We 
observed reduction in plasma levels of the pro-inflam-
matory cytokine TNF-α as well as IL-6, in the absence of 
change to HOMA-IR and C-peptide. Thus, it is possible 
that n-3PUFAs exerts putative inflammatory-modifying 
effects which do not translate to improved insulin sen-
sitivity or beta-cell function. Indeed, inflammatory sig-
nalling is complex and multifaceted and it is likely that 
distinct portions of the inflammatory signalling pathways 
may be affected differentially by n-3PUFAs. Our analysis 
included up to ~ threefold more studies than previous 
meta-analyses (IL-6: 2 vs. 5 RCTs; TNF-α: 2 vs. 6 RCTs) 
[20], and the results are consistent with the hypoth-
esis that n-3PUFA exerts reductions in inflammatory 
markers.
Overall, we observed a small reduction in HbA1c fol-
lowing n-3PUFA supplementation. Earlier work has indi-
cated that n-3PUFAs may result in adverse effects on 
HbA1c in patients with T2DM, from which increased 
basal hepatic glucose output and impaired insulin secre-
tion are postulated to be responsible [48]. Our findings 
are contrary to previous meta-analyses assessing the use 
of n-3PUFAs on HbA1c in T2DM [18–21]. However, it 
is important to highlight that the overall ES for HbA1c 
is substantially increased by two RCTs and sensitivity 
analysis suggests the removal of either one of those trials 
changes the statistical interpretation of the test. Further-
more, we were unable to detect any effect of duration, 
dosage, or an interaction thereof, on HbA1c reduction. It 
is important to note however, that only 14 of the 33 RCTs 
included in this analysis were conducted ≥ 3  months, 
and that no effect was found on other indices of glycae-
mic control (FPG, fasting insulin, HOMA-IR, C-peptide). 
This highlights the requirement for longitudinal research 
to determine the effects of n-3PUFAs on glycaemic con-
trol in T2DM. In keeping with previous literature we 
found no significant changes in systolic or diastolic blood 
pressure following supplementation with n-3PUFAs [20], 
suggesting limited impact on vascular tone.
This meta-analysis and meta-regression provides the 
most comprehensive and contemporary review to date, 
assessing 19 cardiometabolic biomarkers, and including 
45 RCTs—21 more than the largest aggregate data meta-
analysis on this topic, and assessed whether treatment 
dosage, duration or an interaction thereof modify effects. 
By adopting a random-effects approach over fixed-effects 
to account for the true variation in effect size from trial 
to trial [27], and employing meta-regression techniques 
over subgroup analyses [49], our approach advances the 
findings from previous meta-analyses. Despite apply-
ing stringent inclusion criteria and rigorous methodol-
ogy, some limitations must be acknowledged. Although 
no language restrictions were applied during the initial 
search, we were unable to translate 13 RCTs at full text 
stage which may have introduced language bias into the 
review. Sensitivity analyses for 5 outcomes of interest 
revealed that the removal of at least one trial moderated 
the statistical interpretation of the results from signifi-
cant to non-significant. While the present meta-analysis 
had sufficient power to detect small effect sizes, smaller 
regression effects in some variables may have been lost as 
a result of the smaller number of trials due to the specific 
inclusion criteria. In addition, several concerns regarding 
the quality of the available evidence could be made, fur-
ther high-quality evidence to support a beneficial effect 
of n-3PUFAs in T2DM patients could lead to more pre-
cise estimates of overall effect size. EPA and DHA may 
exert differential effects on cardiometabolic risk factors 
[50]. Due to the lack of qualifying studies investigating 
the independent effects of DHA (n = 4) and EPA (n = 9) 
on cardiometabolic risk factors, we were unable to dif-
ferentiate between DHA, EPA, and concomitant admin-
istration. Quantifying the fatty acid composition of blood 
in n-3PUFA supplementation trials offers an objective 
measure of compliance and assessment of interindividual 
variability [51]. We encourage future research to include 
this, at least as a moderator variable, and to consider the 
influence of alternative assessment methods (i.e. plasma 
levels are indicative of acute intake whereas erythrocyte 
Table 1 Summary of meta-regression analysis using 
dosage and duration as covariates on appropriate 
cardiometabolic biomarkers (i.e. ≥ 10 RCTs)
Moderator variable p value Meta-regression of moderator 
variable vs. effect size
Low density lipoprotein
 Duration 0.85 Slope 0.00, 95% CI − 0.01 to 0.01, 
df = 27
 Dosage 0.14 Slope 0.03, 95% CI − 0.01 to 0.07, 
df = 27
Triglycerides
 Duration 0.35 Slope 0.01, 95% CI − 0.01 to 0.01, 
df = 31
 Dosage 0.87 Slope -0.00, 95% CI − 0.07 to 0.08, 
df = 31
Glycated haemoglobin
 Duration 0.11 Slope 0.01, 95% CI − 0.00 to 0.02, 
df = 32
 Dosage 0.55 Slope 0.03, 95% CI − 0.07 to 0.13, 
df = 32
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measurements reflect sustained intake) [52]. Although 
data relating to treatment adherence were not available 
for all studies, inclusion of non-adherent participants 
would bias results towards the null; thus, we can be con-
fident that the effects of n-3PUFA in those who are fully 
adherent to supplementation will be no less than those 
reported for the study population overall. Although not 
possible in our meta-analysis, it would be of benefit to 
confirm findings on patient level data, which allow for 
predictors of supplementation outcome, and enable more 
precise studies in the future; other covariates such as 
duration of diabetes should be considered to see if they 
moderate the effects of n-3PUFAs. This meta-analysis 
intended to assess the effects of n-3PUFAs in both type 
1 diabetes (T1DM) and T2DM, as originally outlined in 
the PROSPERO protocol. Unfortunately, only three RCTs 
investigating people with T1DM met the inclusion cri-
teria (owing to inadequate experimental designs), high-
lighting the requirement for rigorously designed RCTs 
in this cohort. Considering T1DM presents with more 
severe permutations to the metabolic milieu compared to 
T2DM, it is not unreasonable to speculate that favoura-
ble findings from this analysis may translate and be more 
clinically relevant in the context of T1DM.
Conclusions
Our study reports a major new indication for n-3PUFA 
intake: improvement in lipid profile and markers of 
inflammation without adverse effects on LDL or HbA1c. 
Neither duration of supplementation nor dosage of 
n-3PUFAs statistically explain the observed heterogene-
ity meaning that optimal treatment patterns for clinical 
practice are yet to be determined and further research is 
warranted. Future precision medicine trials should aim 
to establish whether interactions between n-3PUFAs and 
cardiometabolic biomarkers are modified by patient level 
characteristics to improve response to supplementation 
in T2DM and whether such improvements are observed 
in T1DM.
Additional file
Additional file 1: Table S1. Predetermined search terms and strategy. 
Table S2. The effect of n-3 PUFAs on indices of glycaemic control. 
Table S3. The effect of n-3 PUFAs on lipid profiles. Table S4. The effect of 
n-3 PUFAs on Inflammatory parameters, and blood pressure. Table S5. 
The effect of n-3 PUFAs on apolipoproteins and non-esterified fatty acids. 
Table S6. Inclusion/exclusion criteria. Table S7. Primary outcome of 
included studies. Figure S1. Risk of bias across expressed as a percentage 
across all included studies. Figure S2. Risk of bias figure. Figure S3 A-G. 
Funnel plot of standard error by standard difference in means for LDL (A), 
TG (B), VLDL-C (C), VLDL-TG (D), TNF-α (E), IL-6 (F), and HbA1c (G). LDL, low 
density lipoprotein cholesterol; TG, triglycerides; VLDL-C, very low density 
lipoprotein cholesterol; VLDL-TG, very low density lipoprotein triglycerides; 
TNF-α, tumour necrosis factor alpha; IL-6, Interleukin 6; HbA1c, glycated 
haemoglobin.
Abbreviations
CVD: cardiovascular disease; CI: confidence intervals; CRP: C-reactive protein; 
DBP: diastolic blood pressure; DHA: docosahexaenoic acid; EPA: eicosapen-
taenoic acid; ES: effect size; FPG: fasting plasma glucose; HbA1c: glycosylated 
haemoglobin; HDL: high density lipoprotein cholesterol; LDL: low-density 
lipoprotein cholesterol; n-3PUFAs: omega-3 polyunsaturated fatty acids; NEFA: 
non-esterified fatty acids; RCTs: randomised controlled trials; SBP: systolic 
blood pressure; SMD: standardised mean difference; T1DM: type 1 diabetes; 
T2DM: type 2 diabetes; VLDL-C: very low-density lipoprotein cholesterol; VLDL-
TG: very low-density lipoprotein triglycerides.
Authors’ contributions
LLO, OJP, KD and MDC designed the protocol. LLO, JM and KD performed the 
searches. LLO and JM independently screened all records identified through 
database searches. LLO and MDC independently extracted all quantitative 
data and assessed the risk of bias. LLO and KD analysed all data. LLO, JM, OJP, 
RAA, KMB, RT, DF, DJW, KD and MDC prepared the manuscript. All authors 
revised the final version of the manuscript. All authors read and approved the 
final manuscript.
Author details
1 Institute for Sport, Physical Activity & Leisure, Leeds Beckett University, 
Leeds LS6 3QS, UK. 2 AGADA Diabetes Education and Research Institute, Lju-
bljana, Slovenia. 3 Multidisciplinary Cardiovascular Research Centre, University 
of Leeds, Leeds, UK. 4 Bradford Institute for Health Research, Bradford Royal 
Infirmary, Bradford, UK. 5 Department of Health Sciences, University of York, 
York, UK. 6 Population Health Research Institute, St George’s, University of Lon-
don, London, UK. 7 The Melbourne School of Population and Global Health, 
The University of Melbourne, Melbourne, Australia. 8 Institute of Cellular Medi-
cine, Newcastle University, Newcastle, UK. 9 Present Address: Leeds Institute 
of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. 
Acknowledgements
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
All data generated or analysed during this study are included in this published 
article and its additional information files.
Consent for publication
Not applicable.
Ethical approval and consent to participate
Not applicable.
Funding
This study was funded by the Institute for Sport, Physical Activity and Leisure 
at Leeds Beckett University, and the AGADA Diabetes Education and Research 
Institute. Neither of the funders were involved in the design, analysis, interpre-
tation, or write-up of this manuscript.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 22 May 2018   Accepted: 28 June 2018
References
 1. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes 
of death in the WHO multinational study of vascular disease in diabetes. 
Diabetologia. 2001;44(Suppl 2):14–21.
 2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-
up of intensive glucose control in type 2 diabetes. N Engl J Med. 
2008;359:1577–89.
Page 12 of 13O’Mahoney et al. Cardiovasc Diabetol  (2018) 17:98 
 3. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein 
HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, 
Genuth S, Ismail-Beigi F, et al. Effects of intensive glucose lowering in type 
2 diabetes. N Engl J Med. 2008;358:2545–59.
 4. Advance Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal 
B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, et al. Intensive 
blood glucose control and vascular outcomes in patients with type 2 
diabetes. N Engl J Med. 2008;358:2560–72.
 5. Kirkman MS, Mahmud H, Korytkowski MT. Intensive blood glucose 
control and vascular outcomes in patients with type 2 diabetes mellitus. 
Endocrinol Metab Clin North Am. 2018;47:81–96.
 6. UK Prospective Diabetes Study. UKPDS) Group. Intensive blood-glucose 
control with sulphonylureas or insulin compared with conventional treat-
ment and risk of complications in patients with type 2 diabetes (UKPDS 
33. Lancet. 1998;352:837–53.
 7. Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ. 
Cardiovascular disease and type 2 diabetes: has the Dawn of a New Era 
arrived? Diabetes Care. 2017;40:813–20.
 8. Lamichhane AP, Crandell JL, Jaacks LM, Couch SC, Lawrence JM, Mayer-
Davis EJ. Longitudinal associations of nutritional factors with glycated 
hemoglobin in youth with type 1 diabetes: the SEARCH Nutrition Ancil-
lary Study. Am J Clin Nutr. 2015;101:1278–85.
 9. Micha R, Penalvo JL, Cudhea F, Imamura F, Rehm CD, Mozaffarian D. Asso-
ciation between dietary factors and mortality from heart disease, stroke, 
and type 2 diabetes in the United States. JAMA. 2017;317:912–24.
 10. Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in 
Greenlandic West-coast Eskimos. Lancet. 1971;1:1143–5.
 11. Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol 
Chem. 2002;277:8755–8.
 12. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J 
Clin Nutr. 1997;65(Suppl 5):1645–54.
 13. Sawada T, Tsubata H, Hashimoto N, Takabe M, Miyata T, Aoki K, Yamashita 
S, Oishi S, Osue T, Yokoi K, et al. Effects of 6-month eicosapentaenoic 
acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin 
secretion ability, and concomitant endothelial dysfunction among 
newly-diagnosed impaired glucose metabolism patients with coronary 
artery disease. An open label, single blinded, prospective randomized 
controlled trial. Cardiovasc Diabetol. 2016;15:121.
 14. Jacobo-Cejudo MG, Valdes-Ramos R, Guadarrama-Lopez AL, Pardo-
Morales RV, Martinez-Carrillo BE, Harbige LS. Effect of n-3 polyunsaturated 
fatty acid supplementation on metabolic and inflammatory biomarkers 
in type 2 diabetes mellitus patients. Nutrients. 2017;9:573.
 15. Fayh APT, Borges K, Cunha GS, Krause M, Rocha R, de Bittencourt PIH, 
Moreira JCF, Friedman R, da Silva Rossato J, Fernandes JR, et al. Effects 
of n-3 fatty acids and exercise on oxidative stress parameters in type 2 
diabetic: a randomized clinical trial. J Int Soc Sports Nutr. 2018;15:18.
 16. Poreba M, Mostowik M, Siniarski A, Golebiowska-Wiatrak R, Malinowski 
KP, Haberka M, Konduracka E, Nessler J, Undas A, Gajos G. Treatment with 
high-dose n-3PUFAs has no effect on platelet function, coagulation, 
metabolic status or inflammation in patients with atherosclerosis and 
type 2 diabetes. Cardiovasc Diabetol. 2017;16:50.
 17. Farmer A, Montori V, Dinneen S, Clar C. Fish oil in people with type 
2 diabetes mellitus. Cochrane Database Syst Rev. 2001. https ://doi.
org/10.1002/14651 858.CD003 205.
 18. Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HA. Meta-analysis of 
the effects of n-3 polyunsaturated fatty acids on lipoproteins and other 
emerging lipid cardiovascular risk markers in patients with type 2 diabe-
tes. Diabetologia. 2007;50:1593–602.
 19. Hartweg J, Perera R, Montori V, Dinneen S, Neil HA, Farmer A. Omega-3 
polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane 
Database Syst Rev. 2008. https ://doi.org/10.1002/14651 858.CD003 205.
pub2.
 20. Hartweg J, Farmer AJ, Holman RR, Neil A. Potential impact of omega-3 
treatment on cardiovascular disease in type 2 diabetes. Curr Opin Lipidol. 
2009;20:30–8.
 21. Chen C, Yu X, Shao S. Effects of omega-3 fatty acid supplementation on 
glucose control and lipid levels in type 2 diabetes: a meta-analysis. PLoS 
ONE. 2015;10:1–14.
 22. Jump DB, Depner CM, Tripathy S. Omega-3 fatty acid supplementa-
tion and cardiovascular disease: thematic review series: new lipid and 
lipoprotein targets for the treatment of cardiometabolic diseases. J Lipid 
Res. 2012;53:2525–45.
 23. Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, Deedwania 
P, Eckel RH, Ershow AG, Fradkin J, et al. Update on prevention of cardio-
vascular disease in adults with type 2 diabetes mellitus in light of recent 
evidence: a scientific statement from the american heart association and 
the american diabetes association. Diabetes Care. 2015;38:1777–803.
 24. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, 
Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement 
for reporting systematic reviews and meta-analyses of studies that 
evaluate healthcare interventions: explanation and elaboration. BMJ. 
2009;339:b2700.
 25. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, 
Savović J, Schulz KF, Weeks L, Sterne JAC. The Cochrane Collaboration’s 
tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
 26. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard 
deviation from the sample size, median, range and/or interquartile range. 
BMC Med Res Methodol. 2014;14:135.
 27. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-
analysis. 1st ed. West Sussex: Wiley; 2009.
 28. Faraone SV. Interpreting estimates of treatment effects: implications for 
managed care. P T PeerRev J Formul Manag. 2008;33:700–11.
 29. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. 
Stat Med. 2002;21:1539–58.
 30. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: 
evaluating the risks and the benefits. JAMA. 2006;296:1885–99.
 31. Kris-Etherton PM, Harris WS, Appel LJ, American Heart Association. Nutri-
tion C. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular 
disease. Circulation. 2002;106:2747–57.
 32. Shearer GC, Savinova OV, Harris WS. Fish oil—how does it reduce plasma 
triglycerides? Biochim Biophys Acta. 2012;1821:843–51.
 33. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty 
acids and coronary heart disease risk: clinical and mechanistic perspec-
tives. Atherosclerosis. 2008;197:12–24.
 34. Adkins Y, Kelley DS. Mechanisms underlying the cardioprotective effects 
of omega-3 polyunsaturated fatty acids. J Nutr Biochem. 2010;21:781–92.
 35. Sandhu PK, Musaad SM, Remaley AT, Buehler SS, Strider S, Derzon JH, 
Vesper HW, Ranne A, Shaw CS, Christenson RH. Lipoprotein biomarkers 
and risk of cardiovascular disease: a laboratory medicine best practices 
(LMBP) systematic review. J Appl Lab Med. 2016;1:214–29.
 36. Wadhera RK, Steen DL, Khan I, Giugliano RP, Foody JM. A review of 
low-density lipoprotein cholesterol, treatment strategies, and its impact 
on cardiovascular disease morbidity and mortality. J Clin Lipidol. 
2016;10:472–89.
 37. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel 
RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, et al. 2013 ACC/
AHA guideline on the treatment of blood cholesterol to reduce athero-
sclerotic cardiovascular risk in adults: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines. 
J Am Coll Cardiol. 2014;63:2889–934.
 38. Bradberry JC, Hilleman DE. Overview of omega-3 fatty acid therapies. 
Pharm Ther. 2013;38:681–91.
 39. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, 
Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein 
concentration and risk of coronary heart disease, stroke, and mortality: an 
individual participant meta-analysis. Lancet. 2010;375:132–40.
 40. Mirza S, Hossain M, Mathews C, Martinez P, Pino P, Gay JL, Rentfro A, 
McCormick JB, Fisher-Hoch SP. Type 2-diabetes is associated with 
elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin 
in a population of Mexican Americans: a cross-sectional study. Cytokine. 
2012;57:136–42.
 41. Tuttle HA, Davis-Gorman G, Goldman S, Copeland JG, McDonagh PF. 
Proinflammatory cytokines are increased in type 2 diabetic women with 
cardiovascular disease. J Diabetes Complications. 2004;18:343–51.
 42. Collaboration Emerging Risk Factors, Kaptoge S, Di Angelantonio E, Pen-
nells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, et al. 
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N 
Engl J Med. 2012;367:1310–20.
 43. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: 
time to start. Nat Rev Drug Discov. 2014;13:465–76.
Page 13 of 13O’Mahoney et al. Cardiovasc Diabetol  (2018) 17:98 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 44. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J 
Clin Invest. 2006;116:1793–801.
 45. Rehman K, Akash MSH. Mechanisms of inflammatory responses and 
development of insulin resistance: how are they interlinked? J Biomed 
Sci. 2016;23:87.
 46. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor 
necrosis factor-alpha: direct role in obesity-linked insulin resistance. Sci-
ence. 1993;259:87–91.
 47. Montane J, Cadavez L, Novials A. Stress and the inflammatory process: a 
major cause of pancreatic cell death in type 2 diabetes. Diabetes Metab 
Syndr Obes. 2014;7:25–34.
 48. Glauber H, Wallace P, Griver K, Brechtel G. Adverse metabolic effect of 
omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann 
Intern Med. 1988;108:663–8.
 49. Burke JF, Sussman JB, Kent DM, Hayward RA. Three simple rules to ensure 
reasonably credible subgroup analyses. BMJ. 2015;351:h5651.
 50. Innes JK, Calder PC. The differential effects of eicosapentaenoic acid 
and docosahexaenoic acid on cardiometabolic risk factors: a systematic 
review. Int J Mol Sci. 2018. https ://doi.org/10.3390/ijms1 90205 32.
 51. Rice HB, Bernasconi A, Maki KC, Harris WS, von Schacky C, Calder PC. Con-
ducting omega-3 clinical trials with cardiovascular outcomes: Proceed-
ings of a workshop held at ISSFAL 2014. Prostaglandins Leukot Essent 
Fatty Acids. 2016;107:30–42.
 52. Harris WS. Assessing fatty acid biostatus: red blood cells or plasma? Lipid 
Technol. 2013;25:179–81.
